VT-1021 is under clinical development by Vigeo Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VT-1021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VT-1021 overview

VT-1021 is under development for the treatment of solid tumors including epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic ductal adenocarcinoma, triple-negative breast cancer and glioblastoma. The drug candidate comprises of D-psaptide and cyclopsaptide, derived from naturally-occurring human protein, prosaposin. It acts by targeting CD36 receptor and administered through intravenous route.

Vigeo Therapeutics overview

Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors. The company is headquartered in Boston, Massachusetts, the US

For a complete picture of VT-1021’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.